Santhera Pharmaceuticals Holding AG Logo

Santhera Pharmaceuticals Holding AG

Develops innovative medicines for rare neuromuscular and mitochondrial disorders.

SANN | SW

Overview

Corporate Details

ISIN(s):
CH1276028821
LEI:
54930035HAOFTTQH0U85
Country:
Switzerland
Address:
HOHENRAINSTRASSE 24, 4133 PRATTELN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for patients with rare diseases. The company targets conditions with high unmet medical needs, primarily in the area of rare neuromuscular and mitochondrial disorders. Santhera's mission is to provide treatment options for diseases that severely impact the lives of affected children and adults and currently have limited or no available therapies. Its development efforts include advanced treatments such as gene therapy for conditions like LAMA2-deficient congenital muscular dystrophy (CMD).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Santhera Pharmaceuticals Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Santhera Pharmaceuticals Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-01-11 N/A Non-Executive member Buy None 42,600.00 CHF
2022-01-10 N/A Executive member Buy None 14,420.00 CHF
2022-01-05 N/A Executive member Buy None 37,000.00 CHF

Peer Companies

Company Country Ticker View
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America 950220
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden NEWBRY
New Nordic Healthbrands AB Logo
Develops and markets herbal supplements & beauty products for natural wellness consumers globally.
Sweden NNH
Newron Pharmaceuticals S.p.A. Logo
Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.
Italy NWRN
NextCell Pharma AB Logo
Develops off-the-shelf cell therapies for autoimmune diseases like type 1 diabetes.
Sweden NXTCL
NGeneBio Co., Ltd. Logo
Provides NGS-based diagnostics, software, and liquid biopsy for precision oncology and healthcare.
South Korea 354200
NIBEC CO., LTD. Logo
Biotech CDMO creating regenerative products with peptide and biomaterial technologies.
South Korea 138610
NIPPON CHEMIPHAR CO., LTD. Logo
Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.
Japan 4539
Nippon Shinyaku Co.,Ltd. Logo
Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.
Japan 4516
NKMAX Co., Ltd. Logo
Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.
South Korea 182400

Talk to a Data Expert

Have a question? We'll get back to you promptly.